Autres langues Alnylam Pharmaceuticals, Inc.

Actions

ALNY

US02043Q1076

Temps réel estimé Cboe BZX Autres places de cotation 15:54:11 10/06/2024			Varia. 5j.	Varia. 1 janv.
152 ^USD	-0,52 %		+1,69 %	-20,07 %

03/06	Un initié d'Alnylam Pharmaceuticals a vendu des actions pour une valeur de 3 224 546 $, selon un récent dépôt auprès de la SEC	MT
07/05	ALNYLAM PHARMACEUTICALS, INC. : HC Wainwright à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Alnylam Pharmaceuticals Insider Sold Shares Worth $3,224,546, According to a Recent SEC Filing	03/06
Alnylam Issues 2023 Corporate Responsibility Report	07/05
Alnylam Pharmaceuticals : 2023 REPORT	07/05
Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed	02/05
Alnylam Pharmaceuticals : Q1 2024 GAAP/Non-GAAP Reconciliation ›	02/05
Earnings Flash (ALNY) ALNYLAM PHARMACEUTICALS Posts Q1 Revenue $494.3M, vs. Street Est of $426.9M	02/05
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Alnylam: Q1 Earnings Snapshot	02/05
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity	02/05
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024	02/05
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia	30/04
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of Their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in Additional Latam and APAC Markets Including Australia	30/04
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results	18/04
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	08/04
Sector Update: Health Care	08/04
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Chevron, Take-Two, Coinbase, Netflix, American Tower...	08/04
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension	08/04
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint	08/04
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...	08/04
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	07/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Alnylam Pharmaceuticals, Inc.

Actions

ALNY

US02043Q1076

Autres langues

Filtres